Population Screening for Chronic Q-Fever Seven Years after a Major Outbreak

PLoS One. 2015 Jul 1;10(7):e0131777. doi: 10.1371/journal.pone.0131777. eCollection 2015.

Abstract

Introduction: From 2007 through 2010, the Netherlands experienced a large Q-fever epidemic, with 4,107 notifications. The most serious complication of Q-fever is chronic Q-fever.

Method: In 2014, we contacted all 2,161 adult inhabitants of the first village in the Netherlands affected by the Q-fever epidemic and offered to test for antibodies against Coxiella burnetii using immunofluorescence assay (IFA) to screen for chronic infections and assess whether large-scale population screening elsewhere is warranted.

Results: Of the 1,517 participants, 33.8% were IFA-positive. Six IFA-positive participants had an IgG phase I titer ≥1:512. Two of these six participants were previously diagnosed with chronic Q-fever. Chronic infection was diagnosed in one of the other four participants after clinical examination.

Conclusions: Seven years after the initial outbreak, seroprevalence remains high, but the yield of screening the general population for chronic Q-fever is low. A policy of screening known high-risk groups for chronic Q-fever in outbreak areas directly following an outbreak might be more efficient than population screening. A cost-effectiveness analysis should also be performed before initiating a population screening program for chronic Q-fever.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Bacterial / blood*
  • Chronic Disease
  • Communicable Disease Control
  • Communicable Diseases / epidemiology
  • Cost-Benefit Analysis
  • Coxiella burnetii
  • Cross-Sectional Studies
  • Disease Outbreaks
  • Female
  • Fluorescent Antibody Technique
  • Humans
  • Immunoglobulin G / blood
  • Male
  • Mass Screening / economics
  • Mass Screening / methods*
  • Middle Aged
  • Netherlands
  • Q Fever / diagnosis*
  • Q Fever / epidemiology*
  • Risk Factors
  • Seroepidemiologic Studies
  • Surveys and Questionnaires

Substances

  • Antibodies, Bacterial
  • Immunoglobulin G

Grants and funding

Financial support provided by Dutch Ministry of Health, Welfare and Sport (VWS) project number 321632. Reduction prices serological IFA testing Laboratory of Medical Microbiology Jeroen Bosch Hospital and of personnel by the Municipal Health Service, Hart voor Brabant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.